When explored in AML, the three drug regimen of decitabine, FLT3i, and venetoclax in FLT3 mutant AML may yield high response rates in the front line (11 of 12 patients with CR (9) or CRp (2)) while more responses with incomplete count recovery were seen in relapse.43 Here, FLT3 is linked to acute myeloid leukemia.